Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab - guidance (TA472)

Source:
National Institute for Health and Care Excellence - NICE
Publication date:
30 August 2017

Abstract

Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for adults with follicular lymphoma that did not respond or progressed after treatment with rituximab.

Guidance development process

How we develop NICE technology appraisal guidance

Next review: The guidance will be updated when the data collection period has ended (expected to be December 2020). Obinutuzumab will continue to be available through the Cancer Drugs Fund while the guidance is being updated, as part of the managed access agreement.